BofA analyst Michael Ryskin raised the firm’s price target on Bruker (BRKR) to $60 from $43 and keeps a Buy rating on the shares. After having spent several days marketing with the company’s CFO in Europe, the firm came away more encouraged by the anticipated 2026 recovery, both for the broader life science tools market and Bruker specifically, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target raised to $55 from $50 at JPMorgan
- Bruker Receives Buy Rating Amid Strong Financial Outlook and Margin Expansion Plans
- Bruker price target raised to $55 from $48 at Wells Fargo
- Bruker price target raised to $55 from $45 at Barclays
- Wolfe upgrades Bruker to Outperform on 2026 growth